380 related articles for article (PubMed ID: 12963650)
1. Utility of tumor markers in determining resectability of pancreatic cancer.
Schlieman MG; Ho HS; Bold RJ
Arch Surg; 2003 Sep; 138(9):951-5; discussion 955-6. PubMed ID: 12963650
[TBL] [Abstract][Full Text] [Related]
2. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
3. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma.
Brown EG; Canter RJ; Bold RJ
J Surg Oncol; 2015 Mar; 111(3):293-8. PubMed ID: 25330934
[TBL] [Abstract][Full Text] [Related]
4. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
Hartwig W; Strobel O; Hinz U; Fritz S; Hackert T; Roth C; Büchler MW; Werner J
Ann Surg Oncol; 2013 Jul; 20(7):2188-96. PubMed ID: 23247983
[TBL] [Abstract][Full Text] [Related]
5. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
6. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer.
Kiliç M; Göçmen E; Tez M; Ertan T; Keskek M; Koç M
Can J Surg; 2006 Aug; 49(4):241-4. PubMed ID: 16948881
[TBL] [Abstract][Full Text] [Related]
7. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma.
Maithel SK; Maloney S; Winston C; Gönen M; D'Angelica MI; Dematteo RP; Jarnagin WR; Brennan MF; Allen PJ
Ann Surg Oncol; 2008 Dec; 15(12):3512-20. PubMed ID: 18781364
[TBL] [Abstract][Full Text] [Related]
8. Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma.
Ong SL; Garcea G; Thomasset SC; Mann CD; Neal CP; Abu Amara M; Dennison AR; Berry DP
J Gastrointest Surg; 2008 Jun; 12(6):1068-73. PubMed ID: 18043987
[TBL] [Abstract][Full Text] [Related]
9. Preoperative prediction of complete resection in pancreatic cancer.
Shah D; Fisher WE; Hodges SE; Wu MF; Hilsenbeck SG; Charles Brunicardi F
J Surg Res; 2008 Jun; 147(2):216-20. PubMed ID: 18498873
[TBL] [Abstract][Full Text] [Related]
10. Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderline resectable pancreatic cancer.
Satoi S; Yanagimoto H; Toyokawa H; Inoue K; Wada K; Yamamoto T; Hirooka S; Yamaki S; Yui R; Mergental H; Kwon AH
Pancreas; 2011 Apr; 40(3):426-32. PubMed ID: 21206325
[TBL] [Abstract][Full Text] [Related]
11. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
[TBL] [Abstract][Full Text] [Related]
12. Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease.
Ritts RE; Nagorney DM; Jacobsen DJ; Talbot RW; Zurawski VR
Pancreas; 1994 Nov; 9(6):707-16. PubMed ID: 7846013
[TBL] [Abstract][Full Text] [Related]
13. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
[TBL] [Abstract][Full Text] [Related]
14. CA19-9 as a predictor of resectability in patients with borderline resectable pancreatic cancer.
He Z; Lu H; Du X; Hu W; Zhaoda BT
Hepatogastroenterology; 2013 Jun; 60(124):900-3. PubMed ID: 23321027
[TBL] [Abstract][Full Text] [Related]
15. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
16. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
17. Preoperative Tumor Markers Independently Predict Survival in Stage III Gastric Cancer Patients: Should We Include Tumor Markers in AJCC Staging?
Lin JX; Wang W; Lin JP; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu R; Zheng CH; Huang CM; Zhou ZW; Li P
Ann Surg Oncol; 2018 Sep; 25(9):2703-2712. PubMed ID: 29971670
[TBL] [Abstract][Full Text] [Related]
18. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
[TBL] [Abstract][Full Text] [Related]
20. Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer.
Yasue M; Sakamoto J; Teramukai S; Morimoto T; Yasui K; Kuno N; Kurimoto K; Ohashi Y
Pancreas; 1994 Nov; 9(6):735-40. PubMed ID: 7846017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]